Plasma amylin levels in migraine and after erenumab treatment: A REFORM study.

This study looked at plasma amylin levels in people with migraine. Researchers wanted to see if these levels differ from healthy controls. Amylin is a peptide linked to migraine attacks. Previous studies showed that an amylin analogue can trigger migraines. However, it was unclear if plasma amylin could distinguish migraine patients from healthy individuals. The study also aimed to find out if amylin levels change with treatment. They focused on people taking erenumab, a medication for migraine prevention. The research involved adults with migraines who had at least four migraine days monthly. Participants were enrolled from the Danish Headache Center between September 2020 and June 2022. Plasma samples were collected under controlled conditions to ensure accuracy. Researchers analyzed these samples to understand the relationship between amylin levels and migraine treatment outcomes. This study could help in developing better migraine treatments based on amylin levels. Clinical relevance: This research may help identify new treatment targets for migraine patients, improving their management and quality of life.